See more : Adams Natural Resources Fund, Inc. (PEO) Income Statement Analysis – Financial Results
Complete financial analysis of Belite Bio, Inc (BLTE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Belite Bio, Inc, a leading company in the Biotechnology industry within the Healthcare sector.
- Cannara Biotech Inc. (LOVFF) Income Statement Analysis – Financial Results
- Stantec Inc. (STN.TO) Income Statement Analysis – Financial Results
- Hytera Communications Corporation Limited (002583.SZ) Income Statement Analysis – Financial Results
- G-Factory Co.,Ltd. (3474.T) Income Statement Analysis – Financial Results
- Fuji Electric Co., Ltd. (FELTF) Income Statement Analysis – Financial Results
Belite Bio, Inc (BLTE)
About Belite Bio, Inc
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 399.00K | 198.00K | 30.00K | 17.00K |
| Gross Profit | -399.00K | -198.00K | -30.00K | -17.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 24.84M | 8.87M | 7.42M | 3.69M |
| General & Administrative | 6.82M | 3.95M | 2.38M | 2.06M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.82M | 3.95M | 2.38M | 2.06M |
| Other Expenses | 0.00 | 166.00K | 126.00K | 0.00 |
| Operating Expenses | 31.67M | 12.82M | 9.80M | 5.74M |
| Cost & Expenses | 31.67M | 12.82M | 9.80M | 5.74M |
| Interest Income | 74.00K | 23.00K | 5.00K | 12.00K |
| Interest Expense | 25.00K | 16.00K | 0.00 | 21.00K |
| Depreciation & Amortization | 139.00K | 198.00K | 30.00K | 17.00K |
| EBITDA | -31.53M | -12.43M | -9.64M | -5.71M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -31.67M | -12.82M | -9.80M | -5.74M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 45.00K | 173.00K | 131.00K | -9.00K |
| Income Before Tax | -31.62M | -12.65M | -9.67M | -5.75M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 9.00K | -173.00K | 126.00K | 1.00K |
| Net Income | -31.63M | -12.48M | -9.79M | -5.75M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.19 | -0.62 | -0.41 | -0.24 |
| EPS Diluted | -1.19 | -0.62 | -0.41 | -0.24 |
| Weighted Avg Shares Out | 26.59M | 19.98M | 24.10M | 24.10M |
| Weighted Avg Shares Out (Dil) | 26.59M | 19.98M | 24.10M | 24.10M |
Why Top-Rated Biotechs Apellis, Belite Are Among The Worst Performers Today
Belite Bio, Inc's (BLTE) CEO Tom Lin on Q2 2022 Results - Earnings Call Transcript
Belite Bio to Host Conference Call on August 11, 2022 to Discuss First Half 2022 Financial Results
Biotech Public Offerings at 10-Year Low
Source: https://incomestatements.info
Category: Stock Reports